Experienced in Acute Myeloblastic Leukemia without Maturation

Dr. Qun Dai

Hematology Oncology | Hematology | Oncology
North Shore Health System Medical Faculty Group Practice Inc
256 Mason Ave, C, 
Staten Island, NY 
Experienced in Acute Myeloblastic Leukemia without Maturation
North Shore Health System Medical Faculty Group Practice Inc
256 Mason Ave, C, 
Staten Island, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Qun Dai is a Hematologist Oncology specialist and a Hematologist in Staten Island, New York. Dr. Dai is rated as an Experienced provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Her clinical research consists of co-authoring 22 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Richmond University Medical Center
Staten Island University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

NORTH SHORE HEALTH SYSTEM MEDICAL FACULTY GROUP PRACTICE INC
256 Mason Ave, C, Staten Island, NY 10305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
View 3 Less Clinical Trials

34 Total Publications

The Tanshinones (Tan) Extract From Salvia miltiorrhiza Bunge Induces ROS-Dependent Apoptosis in Pancreatic Cancer via AKT Hyperactivation-Mediated FOXO3/SOD2 Signaling.
The Tanshinones (Tan) Extract From Salvia miltiorrhiza Bunge Induces ROS-Dependent Apoptosis in Pancreatic Cancer via AKT Hyperactivation-Mediated FOXO3/SOD2 Signaling.
Journal: Integrative cancer therapies
Published: June 20, 2024
Similar Doctors
Gail J. Roboz
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Gail J. Roboz
Hematology Oncology | Oncology | Hematology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Gail J. Roboz
Hematology Oncology | Oncology | Hematology

Weill Medical College Of Cornell

520 E 70th St, 
New York, NY 
 (14.2 miles away)
646-962-2012
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gail Roboz is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Roboz is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Neil D. Palmisiano
Oncology | Hematology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Neil D. Palmisiano
Oncology | Hematology

Rutgers Health-Rwj Scleroderma Program

1 Robert Wood Johnson Pl, 
New Brunswick, NJ 
 (20.1 miles away)
732-828-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neil Palmisiano is an Oncologist and a Hematologist in New Brunswick, New Jersey. Dr. Palmisiano is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Palmisiano is currently accepting new patients.

Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Michele Donato
Oncology | Hematology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Michele Donato
Oncology | Hematology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (20.7 miles away)
201-996-5900
Languages Spoken:
English
See accepted insurances

Michele Donato is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Donato is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. Her top areas of expertise are Multiple Myeloma, Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dai's expertise for a condition
ConditionClose
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile